Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair

Many cancers display increased expression of histone deacetylases (HDACs) and therefore transcriptionally inactive chromatin, resulting in the downregulation of genes including tumour suppressor and DNA repair genes. Histone deacetylase inhibitors (HDACi) are a heterogeneous group of epigenetic therapeutics, showing promising anticancer effects in both pre-clinical and clinical settings, in particular the effect of radiosensitisation when administered in combination with radiotherapy. Radiotherapy remains one of the most common forms of cancer treatment, leading to cell death through the induction of DNA double-strand breaks (DSBs). Cells have developed mechanisms to repair such DSB through two major pathways: non-homologous end-joining and homologous recombination. Here, we explore the current evidence for the use of HDACi in combination with irradiation, focusing on the effects of HDACi on DNA damage signalling and repair in vitro. In addition, we summarise the clinical evidence for using HDACi with radiotherapy, a growing area of interest with great potential clinical utility.

[1]  J. Wong,et al.  HDAC inhibitor, valproic acid, induces p53-dependent radiosensitization of colon cancer cells. , 2009, Cancer biotherapy & radiopharmaceuticals.

[2]  S. Adimoolam,et al.  HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination , 2007, Proceedings of the National Academy of Sciences.

[3]  J. Parvin,et al.  Histone Deacetylases 9 and 10 Are Required for Homologous Recombination* , 2011, The Journal of Biological Chemistry.

[4]  David J. Kerr,et al.  HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy , 2010, Proceedings of the National Academy of Sciences.

[5]  J. Cigudosa,et al.  Preclinical activity of LBH 589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia , 2012 .

[6]  S. Tucker,et al.  Histone Deacetylase Inhibitors Radiosensitize Human Melanoma Cells by Suppressing DNA Repair Activity , 2005, Clinical Cancer Research.

[7]  S. Tucker,et al.  Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of γ-H2AX foci , 2006, Molecular Cancer Therapeutics.

[8]  P. Jeggo,et al.  The influence of heterochromatin on DNA double strand break repair: Getting the strong, silent type to relax. , 2010, DNA repair.

[9]  Peter A. Jones,et al.  Epigenetics in cancer. , 2010, Carcinogenesis.

[10]  K. Camphausen,et al.  Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic , 2011, Journal of cellular and molecular medicine.

[11]  K. Camphausen,et al.  Acute Toxicity in a Phase II Clinical Trial of Valproic Acid in Combination with Temodar and Radiation Therapy in Patients with Glioblastoma Multiforme , 2008 .

[12]  N. Kubota,et al.  Scriptaid, a novel histone deacetylase inhibitor, enhances the response of human tumor cells to radiation. , 2009, International journal of molecular medicine.

[13]  F. Hamdy,et al.  The emerging role of histone deacetylase (HDAC) inhibitors in urological cancers , 2013, BJU international.

[14]  J. Debus,et al.  Enhancement of radiation response in osteosarcoma and rhabdomyosarcoma cell lines by histone deacetylase inhibition. , 2010, International journal of radiation oncology, biology, physics.

[15]  A. Ganesan,et al.  Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential? , 2008, British Journal of Cancer.

[16]  K. Flatmark,et al.  Gastrointestinal toxicity of vorinostat: reanalysis of phase 1 study results with emphasis on dose-volume effects of pelvic radiotherapy , 2011, Radiation oncology.

[17]  Kjersti Flatmark,et al.  Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study. , 2010, The Lancet. Oncology.

[18]  Steven S. Foster,et al.  Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair , 2010, Proceedings of the National Academy of Sciences.

[19]  Q. Mei,et al.  Sensitization to γ-irradiation-induced cell cycle arrest and apoptosis by the histone deacetylase inhibitor trichostatin A in non-small cell lung cancer (NSCLC) cells , 2009, Cancer biology & therapy.

[20]  J. Maruta,et al.  Successful treatment of anaplastic thyroid carcinoma with a combination of oral valproic acid, chemotherapy, radiation and surgery. , 2009, Endocrine journal.

[21]  P. Harari,et al.  Modulation of radiation response by histone deacetylase inhibition. , 2005, International journal of radiation oncology, biology, physics.

[22]  M. Hedayati,et al.  Downregulation of Homologous Recombination DNA Repair Genes by HDAC Inhibition in Prostate Cancer Is Mediated through the E2F1 Transcription Factor , 2010, PloS one.

[23]  D. Hallahan,et al.  Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer. , 2006, Cancer research.

[24]  S. Jackson,et al.  Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining , 2010, Nature Structural &Molecular Biology.

[25]  I. Christensen,et al.  Identification of predictive biomarkers for the histone deacetylase inhibitor belinostat in a panel of human cancer cell lines. , 2008, Cancer biomarkers : section A of Disease markers.

[26]  J. Tainer,et al.  Mre11-Rad50-Nbs1 conformations and the control of sensing, signaling, and effector responses at DNA double-strand breaks. , 2010, DNA repair.

[27]  M. Jung,et al.  Adamantanyl-histone deacetylase inhibitor H6CAHA exhibits favorable pharmacokinetics and augments prostate cancer radiation sensitivity. , 2011, International journal of radiation oncology, biology, physics.

[28]  S. Milstien,et al.  Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy , 2012, Oncogene.

[29]  M. Lübbert,et al.  Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy , 2010, Clinical Epigenetics.

[30]  J. Cigudosa,et al.  Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia , 2011, Leukemia.

[31]  Manel Esteller,et al.  The role of histone deacetylases (HDACs) in human cancer , 2007, Molecular oncology.

[32]  L. Thompson.  Recognition, signaling, and repair of DNA double-strand breaks produced by ionizing radiation in mammalian cells: the molecular choreography. , 2012, Mutation research.

[33]  J. Wolff,et al.  Influence of valproic acid on outcome of high-grade gliomas in children. , 2008, Anticancer research.

[34]  A. Tomkinson,et al.  Targeting abnormal DNA double strand break repair in cancer , 2010, Cellular and Molecular Life Sciences.

[35]  A. Dueñas-González,et al.  Epigenetic therapy and cisplatin chemoradiation in FIGO stage IIIB cervical cancer. , 2010, European journal of gynaecological oncology.